CNS FGF Receptor Peptide for Glucose Tolerance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for obesity and diabetes are limited in efficacy and patient compliance, with a high demand for effective treatments that can improve glucose tolerance and manage prediabetes hyperglycemic episodes.

Innovation Solution

Administering a peptide that binds to central nervous system FGF receptor homodimers, specifically a peptide with the sequence X1-X2-F-X3-X4-X5-V-X6-X7-Q-X8-X9-X10, to treat diabetes or obesity by improving glucose tolerance and managing prediabetes hyperglycemic episodes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current therapies for obesity and diabetes are used, then treatment is provided, but efficacy is limited and patient compliance is poor

Engineering Contradiction:

Improvetreatment efficacyVSAvoidpatient compliance

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent changes the molecular target parameter from peripheral receptors to central nervous system FGF receptor homodimers, fundamentally altering the mechanism of action to improve both efficacy and compliance by addressing the root cause of metabolic disorders through central regulation

Inventive Principle:

Principle #35Parameter changes

2Reliability

If FGF receptor ligands are administered to treat diabetes or obesity, then glucose tolerance improves and body fat reduces, but the complexity of peptide sequence requirements increases

Engineering Contradiction:

Improveglucose tolerance improvementVSAvoidpeptide sequence complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent identifies a specific local region within the FGF receptor binding interface (the phenylalanine residue at position 61 and surrounding amino acids) that is critical for homodimer binding, allowing peptide design to focus on this localized functional element rather than the entire receptor structure

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent segments the FGF receptor binding interface into distinct functional elements, identifying the core binding motif (X1-X2-F-X3-X4-X5-V-X6-X7-Q-X8-X9-X10) that can be independently optimized for homodimer selectivity while maintaining overall peptide functionality

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The peptide effectively treats diabetes, obesity, and prediabetes hyperglycemic episodes by improving glucose tolerance and reducing body fat, with potential for chronic administration through implanted devices or systemic injection.

Implementation Method 1

an agent that binds a central nervous system FGF receptor homodimer

Methodology Applied

Scientific EffectReceptor binding:

Data Source

PatentUS11478527B2FGF receptor ligands for treating diabetes and obesity

Publication Date: 2022.10.25 ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIV

AI summary

Methods for treating diabetes or obesity are provided comprising administering to the subject an amount of an agent that binds a central nervous system FGF receptor homodimer.